ReviewJournal of translational medicine2026
Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endostatin, chronic kidney disease (CKD) and anemia among older people: a secondary analysis of the screening for CKD among older people across Europe (SCOPE) study.Journal of translational medicine · 2026Article
- Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is estimated that by 2040, it will be the 5th highest cause of years of life lost globally due to the aging population and the rising prevalence of age-related diseases such as hypertension and diabetes. Therefore, a deep comprehension of the biological and molecular mechanisms underlying kidney fibrosis is urgently needed to facilitate the development of new therapeutic strategies that can hinder disease progression and simultaneously address the comorbidities associated with CKD. MAIN BODY: In the last years numerous studies have elucidated the complex interplay of various cellular and molecular pathways that contribute to the progression of kidney fibrosis. As a result, several promising therapeutic targets have been identified, paving the way for innovative treatment strategies. These include endogenous (Dickkopf-1, Klotho, and secreted frizzled-related proteins) and exogenous (ICG-001 and relaxin) modulators of the WNT/β-catenin pathway; inhibitors of TGF-β (BMP-7, ncRNA, fresolimumab); sphingosine analogs (fingolimod). In addition to these indirect approaches, therapies with direct antifibrotic activity have also gained significant attention in the field. Among these alternatives, SGLT2 inhibitors and finerenone have emerged as particularly promising options due to the favorable outcomes observed in large-scale clinical trials. These studies have highlighted their effectiveness in slowing disease progression and improving patient outcomes.
conclusionsDespite the encouraging results, additional research is necessary to fully assess the protective roles of these treatments in various clinical contexts. This review aims to synthesize the available data and current insights into this important issue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.